Market Estimated To Witness Growth Due To Rising Prevalence And Improving Diagnosis Rates Of PCOS

The Polycystic Ovary Syndrome (PCOS) Treatment Market is estimated to be valued at US$ 1,086.6 million in 2023 and is expected to exhibit a CAGR of 4.86% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

PCOS is a hormonal disorder common among women of reproductive age. It is characterized by an imbalance of reproductive hormones which can negatively impact menstruation and make it difficult for a woman to become pregnant. Symptoms include irregular or no periods, excess hair growth on the face, chest, back or buttocks, acne, pelvic pain and difficulty becoming pregnant. Treatment aims to combat obesity, regulate menstrual periods, reduce symptoms of excess androgens and improve fertility. Products used include oral contraceptives, anti-androgens, insulin-sensitizing agents and infertility medications.

Market Dynamics:

The global PCOS treatment market is primarily driven by the rising prevalence of PCOS worldwide. According to the NIH, PCOS affects around 1 in 10 women. Factors such as obesity, lifestyle changes and genetic factors have contributed to the increased prevalence of PCOS, driving demand for treatment options. Additionally, improving diagnosis rates are enabling more women to get proper treatment for PCOS. Women are also increasingly aware of the long term impacts of untreated PCOS such as diabetes and heart disease. This is leading them to seek treatment early to manage symptoms and health risks. Moreover, the ongoing development of new drug formulations and combination therapies for effective PCOS management are expected to offer lucrative growth opportunities for market players over the forecast period.


Segment Analysis

The polycystic ovary syndrome (PCOS) treatment market is segmented into medication and devices. The medication segment dominates the market owing to high demand for oral contraceptives and insulin-sensitizing drugs for managing PCOS symptoms and related conditions. Oral contraceptives are widely prescribed due to their advantages of reducing acne, excess hair growth and irregular periods along with providing contraception.

PEST Analysis

Political: Government initiatives aimed at raising awareness about women’s health issues and availability of diagnosis and treatment options have boosted the market growth.
Economic: Rising global healthcare spending provides opportunities for companies to invest in developing advanced treatment options and strengthen market presence.
Social: Increasing social awareness about common women’s health problems and availability of non-invasive treatment options are positively impacting the market growth.
Technological: Continuous research focused on developing novel medications and diagnostic devices along with expanding applications of existing therapies are fueling technological advancements.

Key Takeaways

The Global Polycystic Ovary Syndrome (PCOS) Treatment Market Growth is expected to witness high, exhibiting CAGR of 4.86% over the forecast period, due to increasing awareness about PCOS and availability of effective treatment options.
Regional analysis: North America dominates the global market owing to growing incidence of PCOS, awareness initiatives, and early adoption of advanced therapies.
Key players: Key players operating in the PCOS treatment market are Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Zydus Pharmaceuticals, Inc., Prasco Laboratories, Dr. Reddy’s Laboratories, Cadila Pharmaceuticals, Novartis International AG, Concordia Pharmaceuticals Inc., Covis Pharmaceuticals, Inc., Cardinal Health, Aphena Pharma Solutions Tennessee, Inc., Mylan N.V., Evotec SE, McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin Pharmaceutical and Sun Pharmaceutical Industries Ltd., Bayer AG.



Read More –

Leave a Comment